Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGS) Non Operating Income (2020 - 2025)

Historic Non Operating Income for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to -$4.1 million.

  • GeneDx Holdings' Non Operating Income fell 46162.59% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.5 million, marking a year-over-year increase of 6998.23%. This contributed to the annual value of -$29.4 million for FY2024, which is 85367.67% down from last year.
  • Latest data reveals that GeneDx Holdings reported Non Operating Income of -$4.1 million as of Q3 2025, which was down 46162.59% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, GeneDx Holdings' Non Operating Income ranged from a high of $121.0 million in Q3 2021 and a low of -$18.8 million during Q2 2024
  • Moreover, its 5-year median value for Non Operating Income was $1.6 million (2025), whereas its average is $12.9 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first soared by 2026583.33% in 2021, then plummeted by 52698.71% in 2024.
  • Over the past 5 years, GeneDx Holdings' Non Operating Income (Quarter) stood at $75.6 million in 2021, then plummeted by 78.56% to $16.2 million in 2022, then tumbled by 103.34% to -$541000.0 in 2023, then plummeted by 526.99% to -$3.4 million in 2024, then decreased by 21.96% to -$4.1 million in 2025.
  • Its Non Operating Income was -$4.1 million in Q3 2025, compared to $1.6 million in Q2 2025 and -$1.5 million in Q1 2025.